CPIX

Company Overview — What Does CUMBERLAND PHARMACEUTICALS INC Do?

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. CUMBERLAND PHARMACEUTICALS INC (CPIX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO A. J. Kazimi and employs approximately 80 people, headquartered in NASHVILLE, TN 37203, Tennessee. With a market capitalization of $46M, CPIX is one of the notable companies in the Healthcare sector.

CUMBERLAND PHARMACEUTICALS INC (CPIX) Stock Rating — Reduce (April 2026)

As of April 2026, CUMBERLAND PHARMACEUTICALS INC receives a Reduce rating with a composite score of 37.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CPIX ranks #3,716 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CUMBERLAND PHARMACEUTICALS INC ranks #618 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CPIX Stock Price and 52-Week Range

CUMBERLAND PHARMACEUTICALS INC (CPIX) currently trades at $3.09. The stock lost $0.02 (0.6%) in the most recent trading session. The 52-week high for CPIX is $6.26, which means the stock is currently trading -50.7% from its annual peak. The 52-week low is $1.85, putting the stock 67.0% above its annual trough. Recent trading volume was 17K shares, suggesting relatively thin trading activity.

Is CPIX Overvalued or Undervalued? — Valuation Analysis

CUMBERLAND PHARMACEUTICALS INC (CPIX) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.87x, versus the sector average of 2.75x. The price-to-sales ratio is 1.15x, compared to 1.66x for the average Healthcare stock.

At current multiples, CUMBERLAND PHARMACEUTICALS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CUMBERLAND PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score

CUMBERLAND PHARMACEUTICALS INC (CPIX) earns a quality factor score of 37/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -12.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.9% versus the sector average of -33.1%.

On a margin basis, CUMBERLAND PHARMACEUTICALS INC reports gross margins of 85.7%, compared to 71.5% for the sector. The operating margin is -9.6% (sector: -66.1%). Net profit margin stands at -9.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -15.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CPIX Debt, Balance Sheet, and Financial Health

CUMBERLAND PHARMACEUTICALS INC has a debt-to-equity ratio of 213.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.01x, suggesting adequate working capital coverage. Total debt on the balance sheet is $5M. Cash and equivalents stand at $15M.

CPIX has a beta of 0.73, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for CUMBERLAND PHARMACEUTICALS INC is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CUMBERLAND PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, CUMBERLAND PHARMACEUTICALS INC reported revenue of $40M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-3M. Gross margin was 85.7%. Operating income came in at $-3M.

In FY 2025, CUMBERLAND PHARMACEUTICALS INC reported revenue of $45M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-3M. Gross margin was 85.0%. Revenue grew 17.6% year-over-year compared to FY 2024. Operating income came in at $-3M.

In Q3 2025, CUMBERLAND PHARMACEUTICALS INC reported revenue of $8M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-2M. Gross margin was 88.1%. Revenue grew -8.7% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, CUMBERLAND PHARMACEUTICALS INC reported revenue of $11M and earnings per share (EPS) of $-0.05. Net income for the quarter was $-735,207. Gross margin was 81.4%. Revenue grew 10.0% year-over-year compared to Q2 2024. Operating income came in at $-747,478.

Over the past 8 quarters, CUMBERLAND PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $10M to $40M. Investors analyzing CPIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CPIX Dividend Yield and Income Analysis

CUMBERLAND PHARMACEUTICALS INC (CPIX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CPIX Momentum and Technical Analysis Profile

CUMBERLAND PHARMACEUTICALS INC (CPIX) has a momentum factor score of 35/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

CPIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CUMBERLAND PHARMACEUTICALS INC (CPIX) ranks #618 out of 838 stocks based on the Blank Capital composite score. This places CPIX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CPIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CPIX vs S&P 500 (SPY) comparison to assess how CUMBERLAND PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.

CPIX Next Earnings Date

No upcoming earnings date has been announced for CUMBERLAND PHARMACEUTICALS INC (CPIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CPIX? — Investment Thesis Summary

The quantitative profile for CUMBERLAND PHARMACEUTICALS INC suggests caution. The quality score of 37/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Momentum is weak at 35/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, CUMBERLAND PHARMACEUTICALS INC (CPIX) earns a Reduce rating with a composite score of 37.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CPIX stock.

Related Resources for CPIX Investors

Explore more research and tools: CPIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CPIX head-to-head with peers: CPIX vs AZN, CPIX vs SLGL, CPIX vs VMD.